The debut of autoimmune hepatitis after a new coronavirus infection (COVID-19) in an 11-month-old child
https://doi.org/10.31146/1682-8658-ecg-215-7-156-161
Abstract
In many countries fix cases of severe liver damage in children are recorded. A previous or existing coronavirus infection leads to a disruption in the body’s immune response to infections, which can lead to severe inflammation that caused liver damage. This article describes a clinical case of type 2 autoimmune hepatitis, a high degree of biochemical activity, that debuted in an 11-month-old child after a new coronavirus infection (COVID-19). The presented clinical example demonstrates the need for a thorough and comprehensive examination of children with the first clinical manifestations of liver damage and timely prescription of therapy
About the Authors
T. N. Lebedeva
Medical Academy named after S. I. Georgievsky of Vernadsky CFU; Republican Children’s Clinical Hospital
Russian Federation
Russian Federation
A. Yu. Marchukova
Medical Academy named after S. I. Georgievsky of Vernadsky CFU; Republican Children’s Clinical Hospital
Russian Federation
Russian Federation
K. G. Bondar
Republican Children’s Clinical Hospital
Russian Federation
Russian Federation
References
1. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006 Jan 5;354(1):54-66. doi: 10.1056/NEJMra050408.
2. Union of Pediatricians of Russia. Clinical recommendations. [Autoimmune hepatitis in children]. 2016. (in Russ.)@@ Союз педиатров России. Клинические рекомендации. Аутоиммунный гепатит у детей. 2016.
3. Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014 Mar;60(3):612-7. doi: 10.1016/j.jhep.2013.10.020.
4. Lohse A. W., Mieli-Vergani G. Autoimmune hepatitis. J Hepatol. 2011 Jul;55(1):171-82. doi: 10.1016/j.jhep.2010.12.012.
5. Zachou K., Muratori P., Koukoulis G. K., Granito A., Gatselis N., Fabbri A., Dalekos G. N., Muratori L. Review article: autoimmune hepatitis - current management and challenges. Aliment Pharmacol Ther. 2013 Oct;38(8):887-913. doi: 10.1111/apt.12470.
6. Alvarez F., Berg P. A., Bianchi F. B. et al.International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999 Nov;31(5):929-38. doi: 10.1016/s0168-8278(99)80297-9.
7. Hennes E. M., Zeniya M., Czaja A. J. et al.; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008 Jul;48(1):169-76. doi: 10.1002/hep.22322.
8. Manns M. P., Czaja A. J., Gorham J. D., Krawitt E. L., Mieli-Vergani G., Vergani D. et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-2213. doi: 10.1002/hep.23584.
9. Gleeson D., Heneghan M. A.; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011 Dec;60(12):1611-29. doi: 10.1136/gut.2010.235259.
10. Manns M., Gerken G., Kyriatsoulis A., Staritz M., Meyer zum Büschenfelde K. H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987 Feb 7;1(8528):292-4. doi: 10.1016/s0140-6736(87)92024-1.
11. Boberg K. M., Chapman R. W., Hirschfield G. M., Lohse A. W., Manns M. P., Schrumpf E.; International Autoimmune Hepatitis Group. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011 Feb;54(2):374-85. doi: 10.1016/j.jhep.2010.09.002.
12. Mieli-Vergani G., Heller S., Jara P., Vergani D. et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2009 Aug;49(2):158-64. doi: 10.1097/MPG.0b013e3181a1c265.
13. Gregorio G. V., Portmann B., Karani J., Harrison P., Donaldson P. T., Vergani D., Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001 Mar;33(3):544-53. doi: 10.1053/jhep.2001.22131.
14. Beaune P., Dansette P. M., Mansuy D., Kiffel L., Finck M., Amar C., Leroux J. P., Homberg J. C. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A. 1987 Jan;84(2):551-5. doi: 10.1073/pnas.84.2.551.
15. Bourdi M., Larrey D., Nataf J., Bernuau J., Pessayre D., Iwasaki M., Guengerich F. P., Beaune P. H. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest. 1990 Jun;85(6):1967-73. doi: 10.1172/JCI114660.
16. Muratori P., Granito A., Quarneti C. et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol. 2009 Jun;50(6):1210-8. doi: 10.1016/j.jhep.2009.01.020.
17. Zachou K., Gatselis N., Papadamou G., Rigopoulou E. I., Dalekos G. N. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol. 2011 Sep;55(3):636-646. doi: 10.1016/j.jhep.2010.12.032.
18. Obermayer-Straub P., Perheentupa J., Braun S., Kayser A., Barut A., Loges S., Harms A., Dalekos G., Strassburg C. P., Manns M. P. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology. 2001 Sep;121(3):668-77. doi: 10.1053/gast.2001.27103.
Review
For citations:
Lebedeva T.N., Marchukova A.Yu., Bondar K.G. The debut of autoimmune hepatitis after a new coronavirus infection (COVID-19) in an 11-month-old child. Experimental and Clinical Gastroenterology. 2023;(7):156-161. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-215-7-156-161
Views:
197
Email this article 